Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 297 participants.
Also called NCT06501651
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 297 participants
- Sponsor
- Registry
-
NCT06501651
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT06501651. Randomized; no masking; primary purpose treatment. Start 2024-08-01 (anticipated); primary completion 2025-04-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
- Acronym
- Hyper-Save
- Condition
- Essential Hypertension
- Condition
- Type 2 Diabetes
- Condition
- Nephropathy
- Intervention (Drug)
- Sacubitril/Valsartan
- Intervention (Drug)
- Valsartan
- Lead sponsor
- Sichuan Academy of Medical Sciences
- Collaborator
- The Second Affiliated Hospital of Chongqing Medical University
- Collaborator
- Nanchong Central Hospital
- Collaborator
- The People's Hospital of Leshan
- Collaborator
- The Affiliated Traditional Chinese Medicine Hospital Of Southwest Medical University
- Collaborator
- Chengdu First People's Hospital
- Collaborator
- Mianyang People's Hospital
- Collaborator
- Guang'an people's hospital of Sichuan province
- Collaborator
- Meishan Traditional Chinese Medicine Hospital
- Collaborator
- Qijiang District People's Hospital
- Collaborator
- Meishan People's Hospital
- Collaborator
- The First People's Hospital of Guangyuan
- Collaborator
- Dazhou Central Hospital
Record details
- Record id
cardio:ct-nct06501651- Content hash
e9153dd2f02bc249f4868e59e963a8544f871e373a5df0b36963fb2d032b8527